Advancements in Nanotechnology-Based Vaccines (Nanovaccines)
A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "Vaccine Adjuvants".
Deadline for manuscript submissions: closed (31 July 2023) | Viewed by 526
Special Issue Editors
Interests: gene-based vaccines; gene therapy; flaviviruses; vaccine development; nanoparticles; vaccine and immune response; animal vaccine models; adjuvant development; tumor immunology
Interests: tumor immunology; cell biology; nanoparticle; mRNA vaccine; gene-based vaccines; cancer; infectious disease; flaviviruses; influenza virus; vaccine development; immunotherapy
Interests: mucosal immunology; mucosal vaccines; nanoparticles; gut delivery; vaccine development; infectious disease; antibody engineering; large- animal models; gut organoids
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Vaccination has proven to be the most efficient way to protect humans and animals against various infections, and holds the potential to be used as a therapeutic strategy for other immune-related diseases. The application of nanotechnology has accelerated vaccine development by improving the immunogenicity and stability of vaccine components. In particular, the nanoscale size allows nanovaccines to reach the local draining lymph nodes, where they are taken up and processed by resident APCs, potentially triggering stronger T- and B-cell activation, which correlates with a preventive and therapeutic effect. Multiple strategies using synthetic or biological nanomaterials, as polymer-based, lipid-based, or virus-like nanoparticles, have been described to modulate the immunization outcome and ultimately enabled the rapid response against the current SARS-CoV-2 pandemic. Lipid nanoparticles encapsulating COVID-19 mRNA vaccines by Pfizer/BioNtech and Moderna have been licensed worldwide, counting for billions of immunization doses and showing the potential to reduce the global burden of morbidity and mortality. With the unfolding of the 5th wave of COVID-19 in Europe and waning protection requiring a 3rd vaccination, a new window of opportunity is open for improvement and for alternative strategies.
This Special Issue is now open and is seeking research papers and reviews on nanovaccine research, including design, manufacturing technologies, nanomaterial delivery systems, adjuvant technology and vaccine stability.
Dr. Zifu Zhong
Dr. João Paulo Portela Catani
Dr. Bert Devriendt
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- nanotechnology
- nanovaccines
- lipid nanoparticles
- polymer nanoparticles
- conjugate vaccines
- virus-like particles
- vaccine platforms
- adjuvants
- animal models
- non-viral delivery
- immune response
- vaccine development
- vaccine safety
- COVID-19
- SARS-CoV-2
- coronaviruses
